| Trial Name | Clinicaltrials.gov NCT Number |
|---|---|
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549* |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People with Advanced Solid Tumors | NCT03366116 |
| Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors | NCT04222413 |
| Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | NCT03816345 |
| Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial | NCT03907475 |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients with Tumors That Have Alterations in DNA Repair Genes | NCT05687110 |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | NCT05687136 |
| Studying TAK-243 in Patients with Advanced Cancer | NCT06223542 |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients with Metastatic Solid Cancers | NCT06606990 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 |
| A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | NCT05333458 |
| Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly Selected Solid Tumors (ComBET) | NCT05327010 |
| Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors | NCT05691517 |
| Randomized Trial of Neratinib, a Pan-ErbB Inhibitor Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors (ComboMATCH Treatment Trial N5) | NCT06126276 |
*Study is open only for the following histologic subtypes: clear cell ovarian cancer, anal cancer, granulosa cell ovarian cancer, and ewing sarcoma
** Prior PARP required